These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 35851241)
1. Liquid Biopsy - Possibilities for Monitoring the Therapeutic Response in Non-Small Cell Lung Cancer. Raycheva GA; Ivanov HY; Grudeva-Popova ZG Folia Med (Plovdiv); 2021 Dec; 63(6):839-846. PubMed ID: 35851241 [TBL] [Abstract][Full Text] [Related]
2. Unlocking the future of cancer diagnosis - promises and challenges of ctDNA-based liquid biopsies in non-small cell lung cancer. Reina C; Šabanović B; Lazzari C; Gregorc V; Heeschen C Transl Res; 2024 Oct; 272():41-53. PubMed ID: 38838851 [TBL] [Abstract][Full Text] [Related]
3. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer. Shields MD; Chen K; Dutcher G; Patel I; Pellini B Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272 [TBL] [Abstract][Full Text] [Related]
4. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Guibert N; Pradines A; Favre G; Mazieres J Eur Respir Rev; 2020 Mar; 29(155):. PubMed ID: 32051167 [TBL] [Abstract][Full Text] [Related]
5. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. García-Pardo M; Makarem M; Li JJN; Kelly D; Leighl NB Br J Cancer; 2022 Sep; 127(4):592-602. PubMed ID: 35347327 [TBL] [Abstract][Full Text] [Related]
6. Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer. Romero A; Serna-Blasco R; Calvo V; Provencio M Curr Treat Options Oncol; 2021 Aug; 22(10):86. PubMed ID: 34424428 [TBL] [Abstract][Full Text] [Related]
7. Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Gale D; Heider K; Ruiz-Valdepenas A; Hackinger S; Perry M; Marsico G; Rundell V; Wulff J; Sharma G; Knock H; Castedo J; Cooper W; Zhao H; Smith CG; Garg S; Anand S; Howarth K; Gilligan D; Harden SV; Rassl DM; Rintoul RC; Rosenfeld N Ann Oncol; 2022 May; 33(5):500-510. PubMed ID: 35306155 [TBL] [Abstract][Full Text] [Related]
8. Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer. Marinello A; Tagliamento M; Pagliaro A; Conci N; Cella E; Vasseur D; Remon J; Levy A; Dall'Olio FG; Besse B Cancer Treat Rev; 2024 Sep; 129():102791. PubMed ID: 38963991 [TBL] [Abstract][Full Text] [Related]
9. The role of circulating free DNA in the management of NSCLC. Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523 [TBL] [Abstract][Full Text] [Related]
10. Liquid biopsy in breast cancer: A comprehensive review. Alimirzaie S; Bagherzadeh M; Akbari MR Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931 [TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy and its role in an advanced clinical trial for lung cancer. Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770 [TBL] [Abstract][Full Text] [Related]
12. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future. Scilla KA; Rolfo C Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467 [TBL] [Abstract][Full Text] [Related]
13. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141 [TBL] [Abstract][Full Text] [Related]
14. Overview of the Role of Liquid Biopsy in Non-small Cell Lung Cancer (NSCLC). Ospina AV Clin Oncol (R Coll Radiol); 2024 Oct; 36(10):e371-e380. PubMed ID: 39048406 [TBL] [Abstract][Full Text] [Related]
15. The Implication of Liquid Biopsy in the Non-small Cell Lung Cancer: Potential and Expectation. Ren J; Liu R Methods Mol Biol; 2023; 2695():145-163. PubMed ID: 37450117 [TBL] [Abstract][Full Text] [Related]
17. Liquid biopsy for early diagnosis of non-small cell lung carcinoma: recent research and detection technologies. Chang L; Li J; Zhang R Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188729. PubMed ID: 35436521 [TBL] [Abstract][Full Text] [Related]
18. Single tube liquid biopsy for advanced non-small cell lung cancer. de Wit S; Rossi E; Weber S; Tamminga M; Manicone M; Swennenhuis JF; Groothuis-Oudshoorn CGM; Vidotto R; Facchinetti A; Zeune LL; Schuuring E; Zamarchi R; Hiltermann TJN; Speicher MR; Heitzer E; Terstappen LWMM; Groen HJM Int J Cancer; 2019 Jun; 144(12):3127-3137. PubMed ID: 30536653 [TBL] [Abstract][Full Text] [Related]
19. Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: Findings from an observational cohort study. Myint KZY; Shimabuku M; Horio R; Kaneda M; Shimizu Y; Taguchi J Cancer Treat Res Commun; 2023; 35():100701. PubMed ID: 37094468 [TBL] [Abstract][Full Text] [Related]
20. Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs. Diao Z; Han Y; Zhang R; Li J Biochim Biophys Acta Rev Cancer; 2020 Apr; 1873(2):188363. PubMed ID: 32275933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]